US 8822668

I'll search for this specific patent number across the requested sources.

Let me verify the granted claim set and check the litigation details.

Let me confirm the full claim set (independent claims) for the '668 patent.

US 8,822,668 B2 — Verification Summary

Scope note on sources: I searched the web for the literal number 8822668 and restricted my analysis to hits for that number. I did not directly query USPTO PatentCenter/Public PAIR or the CAFC's own docket system (I have no authenticated access); the bibliographic data below comes from Google Patents, FreePatentsOnline, USPTO.report, DrugPatentWatch and federal court filings, cross-checked against the full patent text supplied to me.

1. Bibliographic data (high confidence)

Sources: https://patents.google.com/patent/[US8822668B2](/patent/US8822668B2)/en; https://www.freepatentsonline.com/8822668.html; https://uspto.report/patent/grant/8822668; https://www.drugpatentwatch.com/p/patent-claims/8822668

Abstract: "The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP."

2. Plain-language overview of the independent claims

Claim 1 — the composition claim (a "molar ratio" LNP). A nucleic acid–lipid particle (a SNALP) containing four things: (a) a nucleic acid payload; (b) a cationic lipid making up 50–65 mol % of the total lipid; (c) a non-cationic lipid making up up to 49.5 mol %, which must be a mixture of a phospholipid and cholesterol (or a cholesterol derivative), with the cholesterol component at 30–40 mol %; and (d) an aggregation-inhibiting conjugated lipid (e.g., a PEG-lipid) at 0.5–2 mol %. In plain terms: a lipid nanoparticle in which the majority of the lipid is the cationic (ionizable) lipid, together with a specified cholesterol fraction and a small PEG-lipid fraction.

Claim 17 — pharmaceutical composition. The claim-1 particle plus a pharmaceutically acceptable carrier.

Claim 18 — method of introducing a nucleic acid into a cell. Contact the cell with the claim-1 particle (in vitro or in the cells of a mammal).

Claim 19 (and possibly claims 20–21) — method claim(s). My retrieved claim listing was truncated at claim 19, whose text begins "A method for the…". In this family the parallel method claims are in vivo delivery of a nucleic acid and treatment of a disease/disorder by administering a therapeutically effective amount of the particle (see sibling US 9,364,435, claims 15–17, https://patents.justia.com/patent/[9364435](/patent/9364435)). I therefore infer but cannot confirm that claims 19–21 of the '668 patent cover in vivo delivery and/or treatment.

Uncertainty flagged: One court-exhibit compilation (D. Del. 1:22-cv-00252, D.I. 316-4) contains a 21-claim set for the same title/patent family in which claim 1 recites "phospholipid comprises from 3 mol % to 15 mol %" rather than "non-cationic lipid comprising up to 49.5 mol %." The two independent bibliographic databases I checked for the '668 number (USPTO.report and DrugPatentWatch) both give the "up to 49.5 mol %" version, so I treat that as the '668 text and read the alternative version as belonging to a sibling in the continuation chain — but I cannot rule out a differing printed claim set without a look at the granted instrument itself.

3. 2026 litigation posture (relevant to this specific patent)

• D. Del. 1:22-cv-00252-JDW — Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Moderna, Inc. and ModernaTX, Inc., filed Feb. 28, 2022. The '668 patent was one of six patents originally asserted (11141378, 8058069, 8492359, 8822668, 9364435, 9504651) — https://www.lexology.com/library/document.ashx?g=f757a8ac-04d3-4d97-bfb0-cd57bebfbf87. However, by the time of trial the case was tried on four patents ('651, '435, '359, '378); the '668 patent does not appear in the March 2026 jury instructions' list of asserted claims (D.I. 712). Supplemental infringement contentions referencing the '668 patent were filed (D.I. 602-7). I could not confirm whether the '668 patent was formally dismissed or merely not selected for trial.
• March 3, 2026 consent judgment / settlement — Moderna consented to judgment of infringement and no invalidity on four asserted patents; $2.25B global settlement ($950M upfront + $1.3B contingent on the appeal below) — https://ktslaw.com/-/media/2026/Kilpatrick-Client-Success-...pdf
• CAFC No. 26-1581 — Arbutus Biopharma Corp. v. Moderna, Inc., on appeal from D. Del. No. 1:22-cv-00252-JDW. The appeal is expressly limited to the district court's adjudication of Moderna's Ninth Defense under 28 U.S.C. § 1498 (government-contractor immunity). Docket activity in 2026: AIPLA amicus motion (June 5, 2026); amicus brief (June 18, 2026); Moderna reply brief (Aug. 14, 2026); order placing the appeal on the November 2026 oral-argument calendar (Aug. 24, 2026). Amici include the U.S. Government, AIPLA, Northwestern University, USIJ, NAM and the Bayh-Dole Coalition. https://www.courtlistener.com/docket/73112791/arbutus-biopharma-corporation-v-moderna-inc/
• Other family litigation listed in the Google Patents record: S.D.N.Y. 1:22-cv-02229 (Acuitas Therapeutics v. Genevant Sciences) and D.N.J. 3:23-cv-04200; the Fed. Cir. related-case statement also lists CureVac SE v. Moderna, Bayer CropScience v. Moderna, GlaxoSmithKline Biologicals v. Moderna and others.

Additional, lower-confidence item: one aggregator lists US 8,822,668 as an Orange Book patent for patisiran (Onpattro) with expiry 2029-04-15 (https://www.pharmakb.com/drug-report/patisiran). This is a single secondary source; I have not verified it against the FDA Orange Book.

Bottom line: US 8,822,668 is one of the "molar ratio" LNP patents in the Protiva/Arbutus family (priority Apr. 15, 2008) claiming a nucleic acid-lipid particle with a 50–65 mol % cationic lipid, ≤49.5 mol % non-cationic lipid (phospholipid + 30–40 mol % cholesterol) and 0.5–2 mol % conjugated lipid, plus composition, cell-delivery and administrative method claims. Its 2026 relevance is as part of the Arbutus/Genevant v. Moderna LNP litigation and the resulting Fed. Cir. appeal No. 26-1581 on § 1498 immunity.

I'll research the litigation history for US patent 8822668 using the sources you specified.

Let me dig into the specific litigation cases referenced and find the case details.

Litigation Report — U.S. Patent No. 8,822,668 ("Lipid formulations for nucleic acid delivery")

Threshold note on scope and identification

I interpreted "8822668" literally as U.S. Patent No. 8,822,668 B2 (the '668 patent), issued September 2, 2014, titled "Lipid formulations for nucleic acid delivery," to Protiva Biotherapeutics Inc., now held by Arbutus Biopharma Corporation (with Genevant Sciences GmbH as exclusive licensee). I excluded results for similarly numbered patents (e.g., unrelated references to a "266 patent" appearing in Kubota/Vermeer, MediaTek, and CoolIT matters, which involve different numbers entirely).

One important caveat that colors everything below: the '668 patent was dropped from the lead U.S. case before trial. Moderna's pretrial submission expressly labels it "the '668 patent U.S. Patent No. 8,822,668 (no longer asserted)," alongside U.S. 8,058,069, which was also dropped in the court-ordered bilateral narrowing. The patents that actually went to judgment/settlement were the '359, '435, '378, and '651 patents. So most of the headline-dollar "8822668 litigation" news concerns a case in which the '668 patent was an original but not a surviving asserted patent.

Known litigation

1. Arbutus Biopharma Corp. & Genevant Sciences GmbH v. Moderna, Inc. & ModernaTX, Inc.

Key docket facts I confirmed: the Feb. 2, 2026 summary-judgment order (D.I. 698) granted in part/denied in part the cross-motions, including a ruling on Moderna's 28 U.S.C. § 1498 government-contractor defense (largely rejected for doses going to the general public); the Feb. 4/18, 2026 rulings applied IPR estoppel to bar certain Moderna obviousness arguments and found a genuine enablement dispute. The '668 patent was not among the patents carried to trial.
Sources: CourtListener D. Del. docket 63119229; Moderna's Statement of Disputed Facts, D.I. 691-3; D. Del. opinion; Moderna settlement PR (Nasdaq); Arbutus/Genevant PR; IPWatchdog.

2. Acuitas Therapeutics Inc. v. Genevant Sciences GmbH & Arbutus Biopharma Corp. (New York)

Sources: CourtListener docket 63169706; DrugPatentWatch — Acuitas v. Genevant.

3. Acuitas Therapeutics Inc. v. Genevant Sciences GmbH (New Jersey) — refiling of the SDNY action

Source: Google Patents litigation link for US8822668.

4. Related U.S. enforcement against Pfizer / BioNTech (context; '668 status not confirmed)

Arbutus/Genevant separately sued Pfizer Inc. and BioNTech SE in the District of New Jersey (docket referenced as 3:23-cv-01876-ZNQ-TJB), filed April 4, 2023, asserting five U.S. patents over Comirnaty. The Google Patents record for the '668 patent lists the New Jersey action 3:23-cv-04200 in its litigation section. As of the March 2026 Arbutus press release, the Pfizer/BioNTech U.S. action remains pending following a favorable Markman ruling in September 2025, with Comirnaty representing roughly two-thirds of global COVID-mRNA vaccine sales. I cannot confirm with high confidence that the '668 patent itself is asserted in the Pfizer/BioNTech action, and I flag that as a limitation.

Sources: Big Molecule Watch brief; CourtListener counterclaim exhibit referencing 3:23-cv-01876; Arbutus PR.

5. Federal Circuit appeal (CAFC 26-1581)

The '668 patent is tagged to this appeal via the underlying Delaware docket, but the appeal concerns the four patents that were actually adjudicated, not the '668 patent specifically.

Source: CourtListener Notice of Appeal, D.I. 761; Unified Patents CAFC case link on Google Patents.

Foreign counterparts (same patent family, different patents — noted for completeness)

The '668 patent belongs to Darts-ip / Google family 41198741, whose foreign members were asserted in a parallel international campaign. These are not U.S. 8,822,668, but they arise from the same family and the same Arbutus/Genevant portfolio:

• Canada — Federal Court, File No. T-704-25 (CA 2,721,333)
• Japan — Tokyo District Court, Case No. 2025 (Wa) 70079 (JP 5,475,753)
• Switzerland — Case O2025 002 (EP 2,279,254)
• UPC — UPC_CFI_191/2025 (EP 2,279,254) and UPC_CFI_192/2025 (EP 4,241,767)
• EPO oppositions against EP 2,279,254 and EP 4,241,767

All of the Moderna-related actions were resolved by the March 3, 2026 global settlement. Separately, Arbutus/Genevant expanded enforcement against Pfizer/BioNTech in 2026, including UPC actions UPC-CFI-0002562/2026 (EP 4,241,767) and UPC-CFI-0002566/2026 (EP 4,495,237) before the Hague local division, plus a Canadian action.

Sources: Pearce IP; JUVE Patent; Moderna settlement agreement excerpt.

IPR / PTAB proceedings

I did not find any inter partes review petition filed directly against U.S. 8,822,668. The closely related U.S. 9,364,435 (a continuation of the '668 application) was challenged by Moderna in an IPR, where the PTAB issued a final written decision rejecting Moderna's invalidity challenge; Moderna's appeal to the Federal Circuit was dismissed for lack of standing. That IPR estoppel finding was later applied by Judge Wolson against Moderna's obviousness defenses in the Delaware case. Because I could not run a dedicated PTAB docket search within the available steps, treat the "no IPR on '668 itself" statement as my best finding rather than a certainty.

Source: IPWatchdog, March 4, 2026.

Summary

Litigation in which U.S. 8,822,668 appears:

1. Arbutus/Genevant v. Moderna — D. Del. 1:22-cv-00252-JDW (filed Feb. 28, 2022; '668 originally asserted, then dropped; settled Mar. 3, 2026).
2. Acuitas v. Genevant/Arbutus — S.D.N.Y. 1:22-cv-02229-MKV (filed Mar. 18, 2022; voluntarily dismissed Aug. 4, 2023).
3. Acuitas v. Genevant — D.N.J. 3:23-cv-04200 (filed Aug. 2023; status not confirmed).
4. CAFC 26-1581 — Moderna's §1498 appeal from the Delaware case ('668 tagged but not itself adjudicated).

The '668 patent was never the patent carried to a merits judgment or verdict in any confirmed case — it was dropped from the Delaware action before trial, and the Acuitas challenge in New York was voluntarily dismissed. No litigation outcome resolves the validity or infringement of the '668 patent's claims specifically.

I'll start by verifying the canonical "no AIA trial proceedings" signal against web-searchable sources, then drill into anything that surfaces.

Let me dig specifically for AIA proceedings naming the '668 patent, and check the related-patent IPRs that surfaced.

The '668 patent is part of the Arbutus LNP family that saw heavy PTAB activity on sibling patents. Let me isolate whether any proceeding actually names '668, and check the current appeal docket.

Proceedings overview

Total AIA trial proceedings on US 8,822,668: zero. The structured PTAB block (USPTO ODP) returns no IPR, PGR, or CBM naming this patent, and my independent web searches surfaced no petition, institution decision, or Final Written Decision (FWD) captioned to the '668 patent — the only PTAB matters that surface for the Arbutus/Protiva LNP family are against sibling patents ('127, '435, '069), not '668. Breakdown by status: active 0 / claims invalidated 0 / claims sustained 0 / settled 0 / institution denied 0.

Bottom line for a defendant: there is no PTAB record to hide behind, and none for the patent owner to point to. Every claim of '668 is untested in an AIA trial — no claim has been canceled, no claim has been confirmed, and no § 315(e)(2) estoppel attaches to '668 from any prior FWD. The patent is therefore not "hardened" by a PTAB win, but neither is it weakened by a claim cancellation. You are litigating claim validity from scratch (or in district court), not importing a PTAB result.

⚠️ Confidence note: I could not rule out an as-yet-unindexed petition (e.g., a 2024–2026 filing by a COVID-vaccine defendant). Nothing in my searches indicates one exists, but verify with a PTAB E2E / PTAB Case Search query on "8822668" before relying on this in a brief or a stay motion.

Proceedings on sibling patents in the same family — context only, NOT proceedings on '668

These are not proceedings on US 8,822,668. I list them because they define the family's PTAB history and the arguments your opponent has already rehearsed. Proceeding numbers below appear in the sources cited; do not attribute them to '668.

IPR2018-00680 — ModernaTX v. Protiva Biotherapeutics / Arbutus (US 9,404,127, "the '127 patent")

• Type: Inter Partes Review
• Filed: 2018 (exact date not established from retrieved sources)
• Status: Claims invalidated (all challenged claims held unpatentable); affirmed on appeal
• Petition grounds: § 102 anticipation (per the Federal Circuit's affirmance and Arbutus's own reporting)
• Final Written Decision: 2019-09-10 — all claims of the '127 patent held invalid as anticipated (Arbutus's characterization: "all claims")
• Appeal: Affirmed by the Federal Circuit in a precedential decision on 2023-04-11. The appeal was held in abeyance pending United States v. Arthrex; after the Supreme Court's 2021-06-21 decision, Arbutus waived its Arthrex challenge and the appeal proceeded (opening brief 2021-10-25; Moderna response 2022-02-24; Arbutus reply 2022-04-26; argued 2022-11-04).
• Defensive value: The family's "non-lamellar" genus is dead. If a demand letter leans on '127, there is a precedential Federal Circuit affirmance of invalidity to cite. That said, it does not invalidate '668.

IPR2018-00739 — ModernaTX v. Protiva Biotherapeutics (US 9,364,435, "the '435 patent")

• Type: Inter Partes Review
• Filed: 2018-03 (petition filed March 2018)
• Status: Mixed — some claims held unpatentable, others sustained
• Final Written Decision: 2019-09-11. Reporting diverges on the split: Arbutus describes the Board as "holding certain claims invalid and upholding" others, while Arbutus elsewhere states the Board "reject[ed] Moderna's arguments challenging the validity of ten of the '435 Patent's twenty claims." Net: a partial invalidation with surviving claims.
• Appeal: Moderna appealed (Fed. Cir. Nos. 2020-1184, -1186, ModernaTX, Inc. v. Protiva Biotherapeutics, Inc.); the appeal was dismissed for lack of standing in December 2021. Because the FWD was never reviewed on the merits by an Article III court, Moderna later argued in D. Del. that no § 315(e)(2) estoppel could flow from it.
• Defensive value: The '435 is the closest sibling to '668 on the lipid-ratio genus. Its partial survival is the best available signal that ratio-range claims of this family can withstand § 103 art — but the record is thin and un-reviewed on appeal.

IPR2019-00554 — ModernaTX v. Arbutus (US 8,058,069, "the '069 patent")

• Type: Inter Partes Review
• Filed: 2019-01-09
• Status: Claims sustained
• Final Written Decision: 2020-07-23 — the Board rejected Moderna's challenge to all claims of the '069 patent.
• Appeal: Affirmed by the Federal Circuit on 2021-12-01 (ModernaTX, Inc. v. Arbutus Biopharma Corp., No. 2020-2329).
• Defensive value: A clean PTAB + CAFC win for the patent owner on the narrowest sibling claim (50–65 mol% cationic lipid; 4–10 mol% phospholipid + 30–40 mol% cholesterol; 0.5–2 mol% conjugate). Expect the patent owner to lead with this. Note it is a different claim scope from '668.

Cross-cutting fact Arbutus has conceded on the record: in IPR2018-00739, IPR2018-00680, and IPR2019-00554, Arbutus argued that "the effects of making changes to the proportion of other components in the lipid particle would be unpredictable." Acuitas has weaponized that admission into § 112 written-description / enablement / indefiniteness attacks on the broader family claims. That is your best non-PTAB lever against '668.

Strategic summary

Claim status of '668: entirely UNTESTED at the PTAB. No claim — independent or dependent — has been canceled through an AIA trial, and none has been confirmed. The three family FWDs above involve '127 (all challenged claims canceled), '435 (partial cancellation), and '069 (sustained); none of those dispositions speaks to the claims of '668. I will not map those outcomes onto '668's claims, because the FWDs did not address them. (For reference, the '668 specification describes the "1:62" formulation — cationic lipid ~56.5–66.5 mol%, cholesterol ~31.5–42.5 mol%, PEG-lipid conjugate ~1–2 mol% — and the "1:57" formulation — cationic lipid ~52–62 mol%, phospholipid + cholesterol ~36–47 mol%, PEG-lipid ~1–2 mol%. That is disclosed-embodiment language, not a certification of claim scope; pull the actual claim set from the patent.)

Estoppel landscape is unusually favorable to a new challenger. Because no IPR was ever filed against '668, there is no § 315(e)(2) estoppel on '668 against any party — not Moderna, not Acuitas, not Pfizer/BioNTech. For a current defendant, the full universe of prior art remains available in district court and at the PTAB. Conversely, the '668 patent's own asserter faces no adverse PTAB findings on this patent. Practical bars to watch instead of estoppel:

• § 315(b) time bar: Moderna was served on 2022-02-28 → IPR-barred for Moderna (and privies) after 2023-02-28. Pfizer/BioNTech were sued on 2023-04-04 → barred after 2024-04-04. A defendant not yet served retains full IPR access.
• § 315(a)(1) bar: Acuitas filed declaratory-judgment actions challenging validity of '668 (S.D.N.Y. 2022-03-18, voluntarily dismissed 2023-08-04; refiled D.N.J. 2023-08-04, No. 3:23-cv-04200). Under § 315(a)(1), a petitioner that previously filed a civil action challenging validity is barred from IPR institution. Acuitas's own prior DJ filings likely foreclose it as an IPR petitioner on '668 — a real constraint on the natural challenger, and worth confirming given the voluntary dismissal.
• Director discretion (2025 practice): search results reflect the Office's current "settled expectations"/parallel-litigation tightening of institution, and Unified Patents is on the Supreme Court's docket (No. 25-1230) attacking it. On a 2008-priority patent already in suit since 2022, discretionary denial is a live risk for any new petition.

Pattern signals. (1) One dominant serial petitioner: Moderna filed three coordinated IPRs against three Arbutus family patents (2018–2019) — and never petitioned against '668, even though '668 is one of six patents it was later sued on. That omission is conspicuous. (2) The patent owner does appeal: Arbutus litigated the '127 invalidation through the Federal Circuit to a precedential loss in 2023. (3) No defensive aggregator appears in the chain for '668 — the challengers are all operating-company defendants (Moderna; Pfizer/BioNTech; and Acuitas as supplier), not Unified Patents-style filers. (4) Term is short: Google Patents lists anticipated expiration 2029-04-15. An IPR on a ~2.5-year-remaining patent is a cost/benefit decision, not a default play.

Litigation overlay (this is where '668 is actually being fought). The patent's own "family litigation" metadata shows: D. Del. 1:22-cv-00252 (Arbutus/Genevant v. Moderna — '668 is one of six asserted patents); S.D.N.Y. 1:22-cv-02229 and D.N.J. 3:23-cv-04200 (Acuitas DJ actions — '668 is one of ten patents challenged as invalid); D.N.J. Arbutus/Genevant v. Pfizer/BioNTech filed 2023-04-04; and a Court of Appeals for the Federal Circuit matter, 26-1581, listed in the patent's litigation metadata (issues and disposition not established from my sources — verify before citing). On 2026-02-02 the D. Del. court (Judge Joshua D. Wolson) ruled on summary judgment, precluding Moderna from challenging several Arbutus patents on obviousness and derivation grounds but preserving enablement for the jury. Press reporting also indicates a global Arbutus/Genevant–Moderna settlement (reported at up to $2.5 billion, announced days before the Delaware jury trial) resolving U.S. and international LNP litigation; exact date and terms were not established from the sources I retrieved, and settlement terms are typically confidential. Do not assume the settlement resolves your exposure — '668 remains live against other parties.

Recommended next steps

1. Verify the null result at the source before filing anything. Run PTAB Case Search / PTAB E2E and the ODP API filtered on 8822668. If a 2024–2026 petition exists, it will change the analysis above from "untested" to a live trial with a statutory FWD deadline one year from institution.
2. Do not cite sibling FWDs as if they decided '668. If opposing counsel (or your own summary-judgment brief) asserts that "the PTAB invalidated the Arbutus LNP claims," pin them to the patent: the canceled claims belong to US 9,404,127 (IPR2018-00680; FWD 2019-09-10; Fed. Cir. affirmed 2023-04-11) and partially to US 9,364,435 (IPR2018-00739; FWD 2019-09-11; appeal dismissed for lack of standing, Dec. 2021). Claims of US 8,822,668 were never before the Board.
3. Attack '668 on § 112, not § 103 alone. The strongest documented line is enablement/written description for the full nucleic-acid genus: Arbutus's own IPR statements that lipid-proportion changes are "unpredictable," and Moderna's D. Del. argument that the asserted patents are "devoid of any mRNA teachings or examples" with mRNA appearing only in "laundry lists." Judge Wolson preserved enablement for the jury on 2026-02-02; that is the road that stayed open.
4. If you are a § 315(b)-clean defendant, decide IPR now. Roughly 2.5 years of term remain (anticipated expiration 2029-04-15). Weigh a petition against (a) the 2025 discretionary-denial climate for older, in-suit patents and (b) the fact that a FWD win on '668 would be the first-ever PTAB judgment on these claims — with no estoppel or adverse precedent running against you.
5. Paper the estoppel asymmetry in any stay motion. There is no AIA proceeding on '668 to stay for, so a § 315 stay request has no IPR anchor unless you file. Conversely, a defendant that has already filed a DJ on validity (Acuitas) is likely § 315(a)(1)-barred and should not be assumed to be a co-petitioner.

I'll research the assignment chain for US 8822668, starting with the assignment records and cross-referencing the corporate history.

Let me try to retrieve specific reel/frame data and cross-reference the corporate and litigation record.

Let me attempt to pull the reel/frame specifics and verify the correspondent of record on the recordings.

Assignment Record Analysis — US 8,822,668 B2 ("Lipid formulations for nucleic acid delivery")

Data-availability caveat (read first): I was able to confirm the corporate chain from the patent's own legal-events record, SEC filings, and litigation pleadings, but the specific reel/frame numbers and the assignment correspondent of record were not retrievable with the tools available to me in this session. The USPTO Assignment Center database itself is not directly queryable here, and no indexed mirror returned the reel/frame strings. Per the no-fabrication constraint, I am not inventing reel/frame numbers. Where reel/frame is unavailable I say so explicitly and cite the Google Patents legal-event entry and the corroborating source instead. Two recorded post-issuance assignment events exist (this is not a "no records" patent).

Inventors

All five are the same inventor group that appears across the sibling Protiva LNP filings ('069, '359, '435, '651, etc.). The 2017 continuation filing receipt lists Protiva Biotherapeutics, Inc. (Burnaby, Canada) as applicant with the identical inventor set (Docket Alarm, US 15/840,933).

Pattern check — no abandonment/fire-sale signal. The "all inventors leave within 12 months" tell is absent. These inventors remained with the corporate successor (Protiva → Tekmira → Arbutus) for years; team members from this program (e.g., Peter Lutwyche, formerly of Protiva) appear in Arbutus leadership after the 2015 rename, and Ian MacLachlan later became part of the Genevant LNP licensing organization. This is a long-tenured, single-employer inventor group — the opposite of the pre-fire-sale pattern.

Original assignee

Protiva Biotherapeutics, Inc. (Burnaby, British Columbia, Canada) — named assignee on the face of the issued patent (FPO record shows "Assignee: Protiva Biotherapeutics, Inc.").

• Line of business: R&D of lipid-nanoparticle (LNP) delivery systems for siRNA. Protiva was acquired by Tekmira Pharmaceuticals Corporation on 30 May 2008 via a share purchase; Tekmira (ticker TKMR) then renamed itself Arbutus Biopharma Corporation (Nasdaq: ABUS) effective on/before 3 August 2015. Protiva remained a wholly-owned subsidiary and was amalgamated into Arbutus Biopharma Corporation in January 2018 (per Arbutus's IPR mandatory notice, PTAB filing).
• Product embodying the claims: The patent's LNP technology is the delivery platform behind Onpattro (patisiran) — the first approved systemic RNA-LNP drug (Alnylam, under license) — and is licensed to multiple mRNA/LNP developers. Arbutus itself is a clinical-stage infectious-disease company (HBV programs imusiran/AB-729 and AB-101) rather than a marketer of the claimed particle.
• Current status of the original assignee: Acquired / amalgamated — Protiva ceased to exist as a separate legal entity in January 2018 when it merged into Arbutus Biopharma Corporation. Arbutus is operating (Nasdaq: ABUS), though as of 2025–26 it has drastically downsized R&D (workforce reduced to ~19 employees) and is monetizing the LNP portfolio.

Assignment timeline

No USPTO assignment record was returned to me directly; the following is reconstructed from the Google Patents legal-events panel for US8822668B2 and corroborated against Arbutus's IPR statement and SEC filings.

• 2014-07-31 (event date; execution date not shown) / recorded 2014-07-31 — Reel/frame not retrievable

  • Conveyance: Assignment of assignors' interest
  • Assignor: Jeffs, Lloyd; Palmer, Lorne; Lam, Kieu; MacLachlan, Ian; Yaworski, Edward
  • Assignee: Protiva Biotherapeutics, Inc., c/o Tekmira Pharmaceuticals Corp.
  • Correspondent: Not retrievable from available sources. The prosecution correspondent of record is Customer No. 20350 – Kilpatrick Townsend & Stockton LLP, Atlanta, GA (per the 2017 filing receipt); this is a large general-practice IP firm and is a prosecution address, not the assignment recorder. Do not treat it as an NPE-mill correspondent — no recurrence pattern is visible.
  • Context: Ordinary employee-inventor assignment to the operating subsidiary at time of filing; internal, non-adversarial.

• 2018-02-20 (event date) / recorded 2018-02-20 — Reel/frame not retrievable

  • Conveyance: Merger
  • Assignor: Protiva Biotherapeutics Inc.
  • Assignee: Arbutus Biopharma Corporation
  • Correspondent: Not retrievable from available sources.
  • Context: Internal corporate reorganization — Protiva amalgamated into its parent Arbutus (the January 2018 amalgamation described in Arbutus's IPR notice). Title consolidation, not a sale or transfer-to-asserter.

No further recorded assignments. Notably, the transfer of enforcement rights to Genevant Sciences GmbH is a license (exclusive-rights grant), not an assignment — title remained with Arbutus, which is why Arbutus still appears as owner/co-plaintiff in every suit. Google Patents lists no recorded license/security agreement on the '668 chain.

Timeline diagram

timeline
    title Ownership of US 8822668
    2008 : Priority filing by Protiva Biotherapeutics
         : Protiva acquired by Tekmira Pharmaceuticals
    2013 : Continuation application filed
    2014 : Inventors assign to Protiva Biotherapeutics
         : Patent issued
    2015 : Tekmira renamed Arbutus Biopharma
    2018 : Protiva merged into Arbutus Biopharma
         : Genevant granted exclusive LNP rights
    2022 : Genevant and Arbutus sue Moderna
    2023 : Genevant and Arbutus sue Pfizer and BioNTech

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The only post-inventor transfer is a merger (Protiva → Arbutus, 2018-02-20 event). The assignee is an operating, Nasdaq-listed biopharma (ABUS, Warminster PA), not a "Holdings/Licensing/Ventures" LLC at a registered-agent address. No single-member DE/TX LLC anywhere in the chain.

2. Known asserter in the chain — not present. Neither Protiva, Tekmira, nor Arbutus appears on any of the referenced NPE lists (Acacia, Marathon, IV, IPNav, Wi-LAN/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, etc.). Arbutus is the plaintiff itself in D. Del. 1:22-cv-00252 and DNJ 3:23-cv-04200, alongside its exclusive licensee Genevant — the opposite profile of a passive NPE plaintiff.

3. Repeat correspondent across the chain — unclear / not assessable. Reel/frame and assignment-correspondent data were not retrievable, so I cannot confirm or refute recurrence. The only correspondent I can identify is the prosecution address (Kilpatrick Townsend, Customer No. 20350), which is a mainstream firm handling operating-company patent work and does not by itself indicate an NPE recording mill. Insufficient evidence to call this signal.

4. Cascading transfers — not present. Only two recorded events across ten years (2014, 2018), both to the same corporate family. No chained LLCs, no shared-principal shell hops, no sub-24-month cascade.

5. Pre-litigation transfer — not present. The last recorded assignment (2018-02-20) precedes the first '668 infringement suit (D. Del., filed 2022-02-28) by roughly four years. The chain was not re-arranged within 6 months of suit; standing rests on Arbutus's long-held ownership plus the Genevant license (a license, not an assignment).

6. Bankruptcy fire-sale — not present. No Chapter 7/11 sale. There was a 2025 restructuring (workforce cuts, HQ exit) and, in March 2026, a $2.25B settlement with Moderna, but no insolvency proceeding and no patent auction.

7. Privateering — unclear (partial). There is a licensing-vehicle assertion structure: Arbutus granted "Exclusive Rights" (including the right to sue) to Genevant Sciences GmbH, a Roivant subsidiary, which co-plaintiffs the suits. However, this is not classic privateering against Arbutus's own competitors — Arbutus retains ownership, co-litigates, and shares proceeds (~$178M received; ~16% Roivant equity stake), and the targets (Moderna, Pfizer/BioNTech) are COVID-vaccine makers, not HBV competitors. I score this not a true privateering signal, but flag it as a license-based enforcement vehicle worth noting.

8. Defensive aggregator — not present. The chain does not terminate at RPX, AST, LOT, Unified, or OIN. The patent remains with Arbutus and is being actively asserted, not neutralized.

Verdict

Operating-company assertion.

The ownership chain is a straightforward corporate succession — inventors → Protiva (2014), Protiva merged into Arbutus Biopharma (2018-02-20) — with no shell entity, no known NPE, no pre-suit reassignment, and no bankruptcy sale. The current owner, Arbutus Biopharma Corporation, is an operating Nasdaq biopharma (ABUS) that developed the LNP technology in-house, licenses it to third parties (Alnylam/Onpattro), and is suing real commercial competitors — Moderna (D. Del. 1:22-cv-00252, filed 2022-02-28) and Pfizer/BioNTech (DNJ 3:23-cv-04200) — for unlicensed use of the claimed particles in their mRNA vaccines. The exclusive-rights grant to Genevant is a license, not a title transfer, and Arbutus remains owner and co-plaintiff throughout.

Verification links:

• USPTO Assignment Center (search "8822668"): https://assignment.uspto.gov/patent/index.html
• Google Patents legal events: https://patents.google.com/patent/[US8822668B2](/patent/US8822668B2)/en#legalEvents
• Litigation: D. Del. 1:22-cv-00252 · D.N.J. 3:23-cv-04200 · CAFC 26-1581

Open item for follow-up: To complete the reel/frame column and the correspondent-of-record analysis (signal 3), the two recordings must be pulled directly from the USPTO Assignment Center (assignment center API / reel-frame index) — this is the one column I could not populate from open sources.

I'll research the prior-art citations for US 8,822,668 specifically. Let me pull the cited references and front-page data.

Let me pull the actual front-page reference list and the citing/cited art for the '668 patent.

Prior-Art Analysis — U.S. Patent No. 8,822,668 B2

"Lipid formulations for nucleic acid delivery" — Yaworski, Lam, Jeffs, Palmer & MacLachlan; Appl. No. 13/928,309; filed Jun. 26, 2013; issued Sep. 2, 2014; priority Apr. 15, 2008 (prov. 61/045,228); assignee Protiva Biotherapeutics (now Arbutus Biopharma / licensed to Genevant Sciences).

0. Scope and an important limitation (read first)

I checked the number literally as 8,822,668 and rejected near-miss hits (e.g., the SEC "8222668" filing ID for PDS Biotechnology, and the several "266" patents in Kubota/Vermeer, MediaTek and CoolIT matters). I have no authenticated PatentCenter/PAIR access, so I worked from indexed mirrors of the USPTO record (Google Patents, FreePatentsOnline, Justia, USPTO.report, DrugPatentWatch) and from court exhibits that reproduce the printed front page of this patent family.

The limitation you need to know: I was not able to retrieve the complete printed front-page "(56) References Cited" list of the '668 patent itself in this session. What I did retrieve is (i) the shared front-page reference list of the direct continuation, US 9,364,435 B2 (Appl. 14/462,441, expressly "Continuation of application No. 13/928,309 … now Pat. No. 8,822,668"), as reproduced in the Acuitas complaint exhibit (S.D.N.Y. 1:22‑cv‑02229, D.I. 1‑5) and in Arbutus's CAFC opening brief; and (ii) FPO's list of related family patents. Because ʼ435 is a straight continuation examined against the same specification, its examiner-cited list is a close but not identical proxy for the '668's own list. I flag every item below by confidence level. Anything I could not verify is labelled as such rather than asserted.

Cross-reference / resolved uncertainty: The earlier summary flagged a conflict in claim 1 between "non-cationic lipid comprising up to 49.5 mol %" and a court-exhibit version reciting "phospholipid comprises from 3 mol % to 15 mol %." The DrugPatentWatch full claim set retrieved now confirms claim 1 = "non-cationic lipid comprising up to 49.5 mol % … comprising a mixture of a phospholipid and cholesterol … wherein the cholesterol … comprises from 30 mol % to 40 mol %" (21 claims). Treat the "3–15 mol %" text as belonging to a sibling in the chain, per the earlier note.

1. What any anticipating reference would have to disclose

Because claim 1 is a numerical-regime claim, the § 102 analysis turns on a single combination. A § 102 reference must disclose, in one document:

Dependent claims 3–16 add siRNA length (19–25 bp), 2′OMe modification, 3′ overhangs, DPPC/DSPC, PEG‑DAG/DAA, PEG‑DMA/DSA, PEG MW ≈2,000 Da, and full encapsulation. The mol % window — not the liposome chemistry as such — is where novelty lives; virtually all cited art pre-dates the concept of a "high-cationic / low-PEG" SNALP.

2. Front-page U.S. patent citations (proxy list — family front page)

These are the older U.S. patent documents carried on the face of the '668/'435 family. All are § 102 background art only; none discloses element (b)+(c)+(d) as a combination.

Related/family patents appearing in FPO's listing for 8,822,668:

3. Foreign/PCT documents cited in the specification (background & incorporation-by-reference)

These appear in the '668 specification itself (high confidence, since I have the specification text):

4. Non-patent literature (front page "Other Publications," partial)

Confirmed from the family front page as reproduced in the Acuitas exhibit (the list is OCR-truncated at "Beale"):

• Arpico, S., et al., "Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection," Proceed. Int'l Symp. Control. Rel. Bioact. Mater. 26:759–760 (1999); and Arpico et al., Il Farmaco 59:869–878 (2004) — novel unsaturated cationic lipids. → No § 102; §103 background for cationic-lipid selection.
• Ballas, N., et al., Biochim. Biophys. Acta 939:8–18 (1988) — quaternary-ammonium-detergent liposomes for TMV-RNA transfer. → No.
• Barinaga, M., Science 266:1326 (1994) — gene-transfer vector commentary. → No.
• Bass, "The Short Answer," Nature 411:428–9 (2001) — RNAi mechanism. → No (enables the nucleic-acid element only).
• Beale, G., et al., "Gene Silencing Nucleic Acids Designed by…" (list truncated) → No.

Additional NPL relied on in the '668 specification (high confidence from the specification text; these are the substantive technical antecedents): Elbashir et al., Genes Dev. 15:188–200 (2001); Hammond et al., Nat. Rev. Genet. 2:110–119 (2001); Wheeler et al., Gene Therapy 6:271 (1999) (SPLP); Worgall (1997), Peeters (1996), Yei (1994), Hope (1998), Felgner (1997), Chonn (1995). None discloses the claimed mol % regime.

5. § 102 bottom line, claim by claim

1. Claim 1 — no anticipating reference among the citations retrieved. Every cited document either (i) pre-dates the PEG-lipid/SNALP era entirely (the bulk of the 1983–1998 U.S. patents), (ii) discloses one element in isolation (US 5,013,556 and US 5,885,613 → PEG/aggregation; US 4,897,355 / 5,264,618 / 5,703,055 → cationic lipid; WO 00/03683 → nucleic-acid encapsulation), or (iii) is the applicant's own same-priority family (US 8,058,069, 8,492,359, 8,283,333, 2004/0142025, 2007/0042031). None teaches the combination of 50–65 mol % cationic lipid + phospholipid/cholesterol mixture with 30–40 mol % cholesterol + 0.5–2 mol % conjugated lipid.
2. Claims 2–16 — no separate § 102 exposure beyond claim 1; they narrow siRNA type/length/modification (2′OMe, 3′ overhangs), phospholipid identity (DPPC/DSPC) and PEG-lipid identity (PEG‑DAG/DAA, PEG‑DMA/DSA, PEG ≈2,000 Da). The Bass/Elbashir RNAi references and the PEG-lipid references individually touch claims 3–5 and 11–14, but none discloses them in the claimed particle.
3. Claim 17 (pharmaceutical composition) — no anticipation; requires the claim-1 particle.
4. Claims 18–21 (methods of introducing/delivering/treating) — the earlier-generated summary correctly flagged that the retrieved claim listing was truncated at claim 19; nothing in the cited art anticipates the method claims independently, because they all require administering the claim-1 particle.

The genuine § 102 exposure is not in the cited art but in the applicant's own earlier "Novel lipid formulations for nucleic acid delivery" family — notably WO 2009/082817 and its U.S. counterpart US 2010/0130588 A1 (Protiva, Dec. 2007 priority). If those have a different inventive entity from the '668 and disclose high-cationic/low-PEG SNALP ratios, they are § 102(e) (pre-AIA) / § 102(a)(2) candidates for claim 1. I could not verify either the inventorship overlap or the precise molar-ratio disclosure in-session, so I state this as a lead to check, not a conclusion. Similarly, the sibling US 8,283,333 should be confirmed as same-family before being ruled out.

6. Contradictions / corrections flagged against the earlier sections

• Resolved: the claim-1 ambiguity in the earlier Patent Summary ("up to 49.5 mol %" vs. "phospholipid 3–15 mol %"). Current retrieval confirms the "up to 49.5 mol % / cholesterol 30–40 mol %" text is the '668 claim 1.
• Upgraded: the earlier "lower-confidence" Orange Book item (patisiran/Onpattro, expiry Apr. 15, 2029) is now corroborated by two independent sources — DrugPatentWatch (NDA 210922‑001, use code U‑2378, "treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis") and TheraRadar (13 OB patents; US 8,822,668 in family 41198741, expiry Apr. 15, 2029).
• New since the earlier sections: a further Arbutus filing, Arbutus Biopharma Corp. v. United States, Fed. Cl. No. 1:26‑cv‑00446, appears in the docket record — consistent with the § 1498 theme of CAFC No. 26‑1581. No new prior-art proceeding specific to the '668 itself was found; as previously noted, the confirmed PTAB challenge was to US 9,364,435, not to the '668.

Confidence statement: the identification, claim text, dates, family relationships and the substantive "no anticipation in the cited art" conclusion are high confidence. The completeness of the front-page citation list is medium — it is reconstructed from the straight continuation's front page plus FPO/Justia records, not from the '668 printed instrument. To close that gap, the authoritative next step is the "References Cited" section of the '668 patent image on USPTO PatentCenter, or the "Cited documents" tab for US8822668 on Espacenet/EPO Global Dossier.

I'll ground this analysis in the prior-art citations and family references I can retrieve for the '668 patent. Let me pull the cited references and the key LNP formulation art.

I have the core prior-art landscape. Let me pin down the exact granted claim scope and a few remaining references cited in the family's validity record.

Obviousness Analysis — U.S. Patent No. 8,822,668 B2 under 35 U.S.C. § 103

0. Scope, premises, and flagged inconsistencies

This analysis builds on the two previously generated sections (patent summary; litigation summary) and does not repeat their bibliographic and litigation content. Two points must be carried forward and one resolved:

• Resolved: the earlier summary flagged that claim 1 might read "phospholipid comprises from 3 mol % to 15 mol %" (from D. Del. D.I. 316-4) rather than "non-cationic lipid comprising up to 49.5 mol %." A third independent reproduction of the '668 claim 1 text (a KRIBB technology-landscape table, reproduced at portal.kribb.re.kr) matches the USPTO.report/DrugPatentWatch version: "a non-cationic lipid comprising up to 49.5 mol % … comprising a mixture of a phospholipid and cholesterol or a derivative thereof, wherein the cholesterol or derivative thereof comprises from 30 mol % to 40 mol %." I therefore treat "up to 49.5 mol %" as the '668 claim 1 text. The "phospholipid 4–10 mol %" language is confirmed to belong to sibling US 8,058,069 (it appears verbatim in Arbutus's prosecution amendment quoted in the Feb. 2026 summary-judgment coverage, and the court described it as the '069 amendment).
• Unresolved: claim count. Google Patents/secondary databases report 21 claims; the printed '668 front page reproduced as Exhibit C to the D. Del. complaint states "23 Claims, 24 Drawing Sheets." I flag this as a live discrepancy; it does not change the § 103 analysis below, which turns on claim 1 and the dependent-claim categories.
• Date note: the task header states April 26, 2026 while the system date is September 30, 2026. Nothing in this analysis depends on which is correct.

1. The claim as it actually issues (post-prosecution, literal)

Claim 1 is a closed 100 mol % lipid system ("comprising"):

Two prosecution facts materially sharpen the § 103 analysis:

1. "About" was deleted from all three numeric ranges during prosecution, and Judge Wolson held (Feb. 2, 2026) that this amendment-based prosecution history estoppel bars Arbutus from asserting equivalents. The claim is therefore bounded literally — exactly the posture in which range-overlap obviousness is most dangerous (In re Peterson, 315 F.2d 924 (CCPA 1963)).
2. The patent (and the '069 sibling) is subject to a terminal disclaimer. That is a practical signal that the examiner/patentee treated the claims as not patentably distinct from a commonly owned family member, but I note the legal caveat that a terminal disclaimer is not itself an admission of § 103 obviousness and cannot be used as proof of it — I flag this as context, not as a ground.

The gap the patentee must defend is narrow. The claimed box (cationic 50–65 / cholesterol 30–40 / conjugated 0.5–2) sits immediately adjacent to the family's own admitted prior art: the "2:40" SNALP (2 mol % PEG-cDMA / 40 mol % DLinDMA / 10 mol % DSPC / 48 mol % cholesterol) and the "2:30" SNALP (2/30/20/48). Both are called "previously described" in the '668 specification.

2. The prior art on the page (and its § 102 status)

Priority is April 15, 2008 (provisional 61/045,228). Pre-AIA § 102(b) critical date ≈ April 15, 2007. This matters because § 103(c) (pre-AIA) disqualifies from § 103 only art that qualifies solely under § 102(e)/(f)/(g) — so § 102(b) art is fully available even though much of it is Protiva/Tekmira's own work.

3. Legal framework applied

• KSR Int'l v. Teleflex, 550 U.S. 398 (2007): where the components are known, the field is the same, and the variables are result-effective, the combination is obvious; a finite number of identified, predictable solutions makes the combination "obvious to try."
• In re Aller, 220 F.2d 454 (CCPA 1955): optimizing a result-effective variable within a disclosed range is routine and obvious absent a showing of criticality/unexpected results.
• In re Peterson, 315 F.2d 924; Titanium Metals v. Banner, 778 F.2d 775 (Fed. Cir. 1985): a claimed range that overlaps or is contained within a prior-art range is prima facie obvious.
• In re Geisler, 116 F.3d 1465 (Fed. Cir. 1997); In re Woodruff, 919 F.2d 1575 (Fed. Cir. 1990): narrow ranges are not patentable on narrowness alone; criticality must be shown by comparison to the closest prior art.
• MPEP § 2144.05(I) (overlapping ranges) and § 2144.04 (obvious to optimize); rebuttal requires results "commensurate in scope" with the claims.

4. Grounds of rejection

Ground 1 (primary) — MacLachlan '031/'910, optionally in view of Heyes 2005

Every claimed range overlaps a range expressly disclosed in the MacLachlan SNALP publications:

Because the four lipid components must sum to 100 mol %, the number of ways to land inside the claim is small and fully enumerated by the reference's own disclosures (2:30:20:48, 2:40:10:48, 5:30:20, etc.). This is the Peterson/Titanium Metals situation almost verbatim.

Motivation: MacLachlan is the same SNALP platform, same payload class, same assignee's own technology; the specification is a formulary road map teaching that the lipid molar ratios are the dial to turn. Reasonable expectation of success: the reference reports that its formulations actually encapsulate siRNA and silence genes.

Ground 2 — MacLachlan '031 + Zimmermann 2006 + Heyes 2005

Zimmermann (the field's benchmark NHP ApoB study) used the 2:40 formulation at 2.5 mg/kg and expressly called for "further optimization … and safety profile characterization." That is a printed, articulated problem statement. Heyes 2005 supplies the direction of the fix: silencing potency tracks the fusogenicity of the cationic lipid, DLinDMA (two double bonds) being the best of the series, and endosomal escape — not uptake — is the limiting step. A POSITA reading those two together would increase the fraction of the fusogenic cationic lipid in the bilayer (and consequently reduce the structural cholesterol/phospholipid fraction) and screen, e.g., 50, 55, 57, 60, 65 mol % DLinDMA with cholesterol in the 30s. That is precisely the claimed box.

Ground 3 — Chen '554 and/or "Jadhav '218" + MacLachlan '031

Both references disclose the same four-lipid architecture and — critically — actual formulations with ≥50 mol % cationic lipid (Chen '554 Table IV: 50, 52, 67; Jadhav '218 Table IV: 50, 52, 61, 67, 68), alongside express ranges of "about 40% to about 50%." Where the prior art already contains working species at 50–52 mol % cationic lipid with cholesterol in the 30s, claim 1's 50–65 range covers the prior art's own worked examples; that is not merely an overlapping range but an overlapping species. Motivation: same field, same problem (potency/tolerability of LNP-siRNA), same components.

Caveat: Chen '554 (Oct. 2006) is § 102(b). Jadhav '218's exact publication date I could not verify; if it published only between April 15, 2007 and April 15, 2008, it is § 102(a)/(e) art and (if commonly owned) potentially reachable by a pre-AIA § 103(c) argument.

Ground 4 — Semple '278 / Semple 2001 + MacLachlan '031 (the "result-effective variable" ground)

Semple 2001 varied DODAP mol % (0/25/30) at the expense of DSPC in DSPC/Chol/DODAP/PEG-Cer vesicles, holding cholesterol at ~45 and PEG-Cer at 3–5 mol %. Semple '278 tested nine formulations in which DSPC, cholesterol, ionizable lipid and PEG-Cer were each moved (55/45/0, 20/45/30, 25/45/25, PEG-Cer 3 vs 5 vs 10). This is express teaching that (i) the ionizable cationic lipid mol % is a result-effective variable and (ii) the natural way to raise it is to reduce the structural lipid. Combined with MacLachlan's broader 2–60 mol % disclosure, that is In re Aller optimization within a disclosed range.

Ground 5 — Admitted prior art (2:30 and 2:40 SNALP) + Heyes 2005 + routine optimization

The '668 specification itself states Example 4 showed the 1:57 SNALP "was more than 10 times as efficacious … compared to a nucleic acid-lipid particle previously described ('2:30 SNALP')," and that FIG. 2 compares to a "previously described ('2:40 SNALP')." Those admissions establish the 2:30 and 2:40 formulations as prior art on this record.

But the comparison points are not the closest prior art. The claim's boundaries are 50 and 65 mol % cationic and 30 and 40 mol % cholesterol; the endpoint data compare 57.1 mol % against 30 and 40 mol % cationic and against 48 mol % cholesterol. Under Geisler/Woodruff, criticality requires a showing at the boundary (e.g., 49.9 vs 50.1 mol %). Worse for patentability, the '668's own intermediate formulations (Table 6: 1.4/57.1/7.1/34.3 vs 1.5/61.5/36.9 vs 1.2/61.8/37.1 vs 1.3/68.1/30.6) show a flat potency profile across and beyond the claimed window, and the record in the parallel '069 IPR (IPR2019-00554) shows the 1:57 species tracking a 40.4 mol % cationic formulation (Sample 12) across an in vitro dose–response. Flat response inside the range is the opposite of criticality.

Ground 6 — Heyes 2005 + the SNALP platform, standing alone

Heyes 2005 teaches the mechanistic rule: more fusogenic cationic lipid → more endosomal release → more silencing. The '668 claim 1 is, functionally, "a SNALP with a majority-fusogenic-cationic-lipid bilayer, low PEG, and a specified cholesterol fraction." A POSA applying Heyes's rule to the admitted SNALP platform would arrive at the claim by routine screening. In KSR terms, this is a design incentive with predictable results.

5. Dependent claims and the method claims

• Claims to the nucleic acid being siRNA/interfering RNA, to DLinDMA (or DLin-K-C2-DMA/"XTC2") as the cationic lipid, to cholesterol/cholesterol derivatives (cholestanol, cholesteryl-2′-hydroxyethyl ether, etc.), to PEG-DAA/PEG-cDMA with PEG ~2000 Da, to a lipid:nucleic-acid mass ratio of 5–15, and to a mean diameter of 40–150 nm: each is disclosed or rendered obvious by MacLachlan '031, Zimmermann 2006, Morrissey 2005 (Nat. Biotechnol. 23:1002), WO 2006/053430 and Heyes 2005. Note that the '668's own XTC2-supporting provisional (61/104,212, Oct. 9, 2008) postdates the priority date — it cannot be prior art against the '668, so XTC2 claims must be evaluated against other dioxolane-lipid art rather than that document.
• Claim 17 (pharmaceutical composition): obvious — the '069 IPR record quotes express disclosure of pharmaceutical carriers in the family specification ("Many pharmaceutically acceptable carriers may be employed…").
• Claims 18–21 (introducing a nucleic acid into a cell; in vivo delivery; treatment): obvious — the same record quotes the family specification's express recitations of "contacting the cell with a lipid particle" and "administering to a mammalian subject a lipid particle," and the prior art (Zimmermann 2006) had already administered SNALP-siRNA intravenously to non-human primates.

Any claim whose only added limitation is a sub-range within MacLachlan's disclosed ranges (e.g., 56.5–66.5 or 52–62 mol % cationic) is a fortiori obvious under Peterson/Woodruff.

6. The best non-obviousness positions (and how they fare)

1. Unexpected results (the patentee's principal argument). Arbutus argued during '069 prosecution, and the '668 specification asserts, that "SNALP formulations having increased amounts of cationic lipid … provide unexpectedly superior advantages," supported by the >10× efficacy of 1:57 over 2:30. Weaknesses: (i) only one species inside the claimed genus was tested; (ii) the results are not commensurate in scope with 50–65 / 30–40 / 0.5–2; (iii) the specification's own Table 6 shows comparable activity for formulations above the range (68.1 and 67.8 mol % cationic; 30.5–30.6 mol % cholesterol), which reads as a smooth trend rather than a critical boundary; (iv) the closest prior art is 49.9/65.1 mol %, not 30/40 mol %.
2. Teaching away. A POSA could argue the art taught low cationic-lipid fractions for tolerability (the 2:30 and 2:40 formulations; Semple's 25–30 mol % DODAP systems) and that surface cationic charge drives clearance/toxicity — and that claim 1 simultaneously lowers the PEG-lipid (0.5–2 mol %) relative to the art's 3–10 mol %, which the art taught was needed to shield the cationic bilayer. This is the strongest available argument, but it is not supported by any reference I found that expressly disparaged a majority-cationic bilayer; without such a statement, it is an argument about what the art "would have suggested," which KSR discounts.
3. Unpredictability of the platform. The '069 IPR petition (using the patentee's own data) argues minor changes matter — Samples 2/7 (2/40/10/48) vs. Sample 12 (1/40.4/10.1/48.5) differ by ~0.4 mol % and reportedly differ in potency. That cuts for the patentee (no predictability) and against (no criticality at the claim boundary). I would expect it to be a wash.
4. § 103(c) (pre-AIA). Because most primary references are Protiva/Tekmira work, common ownership must be checked — but this only disqualifies art that is solely § 102(e)/(f)/(g) art. US 2006/0008910 A1, US 2006/0240554 A1, WO 2006/053430, Heyes 2005, Zimmermann 2006, Morrissey 2005 and Semple 2001 are all § 102(b) art and remain fully available. A properly constructed obviousness case should therefore be built on the pre-April-15-2007 publications, not on US 2007/0042031 (§ 102(b) by two months — fine, but tighter) or on Jadhav '218.

7. Bottom line

Claims 1–21 of US 8,822,668 are, on the art of record, prima facie obvious under § 103. The strongest ground is US 2006/0008910 A1 (or US 2007/0042031 A1) in view of Heyes 2005 and Zimmermann 2006: the reference discloses the identical four-component SNALP with overlapping ranges for every claimed component, the secondary references supply both an express problem statement (Zimmermann's call for further optimization of the 2:40 formulation) and a mechanistic direction of modification (increasing the fusogenic cationic-lipid fraction, Heyes), and the remaining step is optimization of a result-effective variable within a disclosed range (In re Aller, In re Peterson), from a finite and enumerated set of solutions (KSR). US 2006/0240554 A1 (Table IV: 50, 52, 67 mol % cationic) and WO 2006/053430 (the 2:30 and 2:40 formulations, which the '668 specification itself admits as "previously described") independently supply species inside or immediately adjacent to the claimed box.

The case turns almost entirely on objective evidence: whether Arbutus's 1:57 vs. 2:30/2:40 data establish criticality or an unexpected result "commensurate in scope" with the claims. On the record I can see, the data cover one species within the genus, compare against non-adjacent prior art (30/40 vs. 48 mol % cholesterol), and show a flat response well outside the range — which is a weak foundation for rebuttal. Practically, however, no tribunal has ever adjudicated the '668 claims: it was dropped from the D. Del. case before trial (settled March 3, 2026) and voluntarily dismissed in S.D.N.Y., so this analysis is prospective.

Items I could not verify and flag explicitly: (i) the granted claim count (21 vs. 23); (ii) the full text of dependent claims 2–16 and 19–21 of the '668; (iii) the publication number and date of "Jadhav '218"; (iv) the exact patent number behind the litigation nickname "MacLachlan '189"; and (v) whether any IPR petition was ever filed against the '668 itself (none found; siblings '435 and '069 were challenged).

Sources: Google Patents US8822668B2; D. Del. 1:22-cv-00252 D.I. 1-3 (Exhibit C, '668 front page); D.I. 667-27 and 667-28 (Anderson opening report, prior-art mapping); IPR2019-00554 petition re '069; Heyes et al. 2005, PubMed 16054724; Zimmermann et al. 2006, Nature 441:111 via cited formulations; Feb. 2026 summary-judgment coverage (prosecution history estoppel, "Molar Ratio Patents"); KRIBB landscape table reproducing '668 claim 1.